Jyong Biotech

Jyong Biotech FCF Yield

The Free Cash Flow Yield of Jyong Biotech (MENS) as of Nov 20, 2026 is -2.58 %. In the previous year, Free Cash Flow Yield was -3.08 % — a change of -16.09% (higher).

FCF Yield

-2.58 %

YoY

-16.09%

Last updated:

Free Cash Flow Yield of Jyong Biotech is 2025 -2.58 % . Free Cash Flow Yield of Jyong Biotech was 2024 -3.08 % . It decreases by -16.09% higher compared to the previous year.

The Jyong Biotech FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2020
-1.00 USD
Jan 1, 2021
-1.80 USD
Jan 1, 2022
-2.73 USD
Jan 1, 2023
-2.21 USD
Jan 1, 2024
-3.08 USD
Jan 1, 2025
-2.58 USD
The Jyong Biotech FCF Yield history
YEARFCF YieldYoY
-2.58 %-16.09%
-3.08 %+39.33%
-2.21 %-19.15%
-2.73 %+51.67%
-1.80 %+80.51%
-1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jyong Biotech Stock analysis

What does Jyong Biotech do? Jyong Biotech Ltd. develops and commercializes plant-derived biotechnology products, focusing on urinary system diseases. The company's primary product is MCS-2, a botanical drug candidate for benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS), and PCP, a clinical-stage botanical drug candidate for prostate cancer prevention. These products target markets in the United States, European Union, and Asia. The firm generates revenue through the development and eventual commercialization of these innovative botanical drug candidates, with MCS-2 and PCP representing key stages in its pipeline. Jyong Biotech's business model centers on advancing its botanical drug candidates through clinical and preclinical stages. The company employs 29 full-time employees to manage research, development, and commercialization efforts. Its focus on plant-derived treatments for urinary system diseases positions it to serve patients and healthcare providers in the U.S., EU, and Asian markets. The firm's revenue streams will primarily come from the successful development and sale of MCS-2 and PCP once they reach commercialization. The company's product portfolio includes MCS-2, PCP, and other preclinical-stage botanical drug candidates. These products are developed for specific medical conditions, with MCS-2 targeting BPH/LUTS and PCP targeting prostate cancer prevention. The firm's strategy involves leveraging its botanical drug development expertise to enter key global markets. Revenue will be generated once these products are approved and sold in the U.S., EU, and Asia. Jyong Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jyong Biotech stock

Free Cash Flow Yield of Jyong Biotech is -2.58 % in 2025.

Free Cash Flow Yield of Jyong Biotech changed from -3.08 % to -2.58 %, representing a -16.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Jyong Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Jyong Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Jyong Biotech

All Key Metrics — Jyong Biotech